<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226277</url>
  </required_header>
  <id_info>
    <org_study_id>4914g</org_study_id>
    <secondary_id>GO01306</secondary_id>
    <nct_id>NCT01226277</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma</brief_title>
  <official_title>An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered Daily in Patients With Refractory Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase I dose-escalation study designed to assess the&#xD;
      safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid&#xD;
      tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in vital signs, ECGs, and clinical laboratory results</measure>
    <time_frame>Throughout study or until early discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities and adverse events of special interest</measure>
    <time_frame>Throughout study or until early discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature, and severity of all adverse events and serious adverse events</measure>
    <time_frame>Throughout study or until early discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of GDC-0917 (including total exposure, maximum and minimum serum concentration, time to maximum observed plasma concentration, elimination of half-life, accumulation at steady-state)</measure>
    <time_frame>Throughout study or until early discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Solid Cancers</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0917</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented, locally advanced or metastatic solid&#xD;
             tumors or lymphoma for which standard therapy either does not exist or has proven&#xD;
             ineffective or intolerable&#xD;
&#xD;
          -  Life expectancy &gt;/= 12 weeks&#xD;
&#xD;
          -  Adequate hematologic and end organ function&#xD;
&#xD;
          -  For female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential, agreement (by patient and/or partner) to use an effective form&#xD;
             of contraception and to continue its use for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant history of chronic liver disease, active hepatic infection,&#xD;
             evidence of hepatic cirrhosis or Grade &gt;/= 2 liver dysfunction not due to hepatic&#xD;
             metastases of cancer, current alcohol abuse, active infections with hepatitis B virus,&#xD;
             or hepatitis C virus&#xD;
&#xD;
          -  Grade &gt;/= 2 fever or associated constitutional symptoms, or a clinically significant&#xD;
             systemic infection within the last month&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  History of clinically significant pulmonary disease&#xD;
&#xD;
          -  Need for chronic and continuous systemic or topical corticosteroids or&#xD;
             immunosuppressive therapy within 2 weeks prior to study entry or anticipated need of&#xD;
             continuous systemic corticosteroids or immunosuppressive therapy during study&#xD;
             participation.&#xD;
&#xD;
          -  Allergy or hypersensitivity to components of the GDC-0917 formulation&#xD;
&#xD;
          -  Palliative radiotherapy within 2 weeks prior to first dose of study drug treatment in&#xD;
             Cycle 1&#xD;
&#xD;
          -  Experimental therapy within 4 weeks prior to first dose of study drug treatment in&#xD;
             Cycle 1&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury within 4 weeks prior to first&#xD;
             dose of study drug treatment in Cycle 1, or anticipation of the need for major surgery&#xD;
             during the course of study treatment&#xD;
&#xD;
          -  Prior anti-cancer therapy within 4 weeks before the first dose of study drug treatment&#xD;
             in Cycle 1&#xD;
&#xD;
          -  All acute drug-related toxicities must have resolved prior to study entry, except for&#xD;
             alopecia and Grade 1 neuropathy&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease excluding cancer&#xD;
&#xD;
          -  History of clinically significant cardiac dysfunction&#xD;
&#xD;
          -  History of malabsorption or other condition that would interfere with enteral&#xD;
             absorption&#xD;
&#xD;
          -  Any history of active GI bleeding within the past 6 months prior to screening&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Uncontrolled ascites, due to diseases other than cancer, requiring weekly large-volume&#xD;
             paracentesis for 3 consecutive weeks prior to enrollment&#xD;
&#xD;
          -  Pregnancy, lactation, breastfeeding or unwillingness to use birth control during the&#xD;
             study and for 3 months after the last dose of GDC-0917&#xD;
&#xD;
          -  Known brain metastases that are untreated, symptomatic, or require therapy to control&#xD;
             symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia Portera, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>98229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

